To examine the extent of weight gain in the first year of treatment in an early psychosis program.
Method:
Subjects were 114 individuals who had experienced a first episode of psychosis and had completed 1 year in a comprehensive first-episode program. Weight and body mass index were calculated on entry to the program and at 6 and 12 months. Most of the subjects were all being prescribed second-generation antipsychotics.
Results:
Significant increases in mean weight were observed in these young individuals over the course of the first year of treatment.
Conclusions:
If we are to work toward optimum treatment for first-episode subjects then potential weight gain needs to be addressed at the beginning of treatment and monitored during treatment.
AllisonDBMentoreJLMoonseongHChandlerLPCappelleriJCInfanteMC, and others. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry1999;60:215–20.
2.
GreenAPatelJKGoismanRMAllisonDBBlackburnG.Weight gain from novel antipsychotic drugs: Need for action. Gen Hosp Psychiatry2000;22:224–35.
3.
AllisonDBMentoreJLMoonseongHChandlerLPCappelleriJCInfanteMC, and others. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry1999;156:1686–96.
4.
Centers for Disease Control. Update: Prevalence of overweight among children, adolescents, and adults—United States, 1988–1994. MMWR Morb Mortal Week Rep1997;46:198–202.
5.
KuczmarskiRJFlegalKMCampbellSMJohnsonCL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960–1991. JAMA1994;272:238–9.
6.
TsuangMTPerkinsKSimpsonJC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry1993;44:4–6.
7.
TaylorDMMcAskillR.Atypical antipsychotics and weight gain: A systematic review. Acta Psychiatr Scand2000;101:416–32.
8.
WirshingDAWirshingWCKysarLBerisfordMAGoldsteinDPashdagJ, and others. Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry1999;60:358–63.
9.
DossFW. The effect of antipsychotic drugs on body weight: A retrospective review. J Clin Psychiatry1979;40:528–30.
10.
StantonJM. Weight gain associated with neuroleptic medication: A review. Schizophr Bull1995;21:463–72.
11.
BeasleyCMTollefsonGDTranPV. Safety of olanzapine. J Clin Psychiatry1997;58(Suppl 10):1–7.
12.
TollefsonGDBeasleyCMTranPVStreetJSKruegerJATamuraRN, and others. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry1997;154:457–65.
13.
Van BruggenMJLinszenDHDingemansPMLeniorME. A long term comparison of olanzapine and risperidone on weight gain as side effect in adolescents with recent onset schizophrenia. Schizophr Res2001;49:290.
14.
UmbrichtDSPollackSKaneJM. Clozapine and weight gain. J Clin Psychiatry1994;55(Suppl B):157–60.
15.
LeadbetterRShuttyMPavalonisDViewegVHigginsPDownsM.Clozapine-induced weight gain: Prevalence and clinical relevance. Am J Psychiatry1992;149:68–72.
16.
BassonBRKinonBJTaylorCCSzymanskiKAGilmoreJATollefsonGD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry2001;62:23–8.
17.
KellyDLConleyRRHornDSUshchakCM. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol1998;8:15–9.
18.
BrecherMRakIWMelvinKJonesAM. The long-term effect of quetiapine (SeroquelTM) monotherapy on weight in patients with schizophrenia. Int J Psychiatr Clin Pract2000;4:287–91.
19.
WetterlingTMubigbrodtH.Weight gain: Side effect of atypical neuroleptics?J Clin Psychopharmacol1999;19:316–21.
20.
AddingtonJAddingtonD.Early intervention for psychosis: The Calgary early psychosis treatment and prevention program. CPA Bulletin2001;33:11–6.
21.
LarsenTKMcGlashanTHMoeLC. First-episode schizophrenia: Early course parameters. Schizophr Bull1996;22:241–56.
National Institutes of Health National Heart Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda (MD): U.S. Department of Health and Human Services; 1998.
25.
National Institutes of Health National Heart Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res1998;6(Suppl 2):51S–209S.
26.
DouketisJDFeightnerJWAttiaJAFeldmanWF. Periodic health examination, 1999 update: 1. Detection, prevention and treatment of obesity. CMAJ1999;160:513–25.
27.
AddingtonJ.Group treatment for smoking cessation in schizophrenia. Psychiatr Serv1998;49:92–8.
28.
AddingtonJEl-GuebalyN.Group treatment for substance abuse in schizophrenia. Can J Psychiatry1998;43:84–5.
29.
AddingtonJAddingtonD.Neurocognitive and social functioning in schizophrenia. Schizophr Bull1999;25:173–83.
30.
BeaulieauMD. Screening for diabetes mellitus in the non pregnant adult. In: Report of the Canadian Task Force on the Periodic Health Examination. Ottawa (ON): Minister of Supply and Services Canada1994; p 602–9.
31.
LoganAG. Lowering the blood total cholesterol level to prevent coronary heart disease. In: Report of the Canadian Task Force on the Periodic Health Examination. Ottawa (ON): Minister of Supply and Services Canada; 1994; p 650–69.
